BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung BioNTech treibt Onkologiestrategie mit dem Fokus auf zwei tumorübergreifende (Pan-Tumor)-Programme sowie Kombinationsansätze weiter voran, um das gesamte Spektrum von Krebserkrankungen vom frühen bis zum späten Stadium abzudeckenPräsentation erster Zwischenergebnisse aus einer globalen Phase-2-Studie mit dem bispezifischem anti-PD-L11xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigte ermutigende Anti-Tumor-Aktivität und ein kontrollierbares Sicherheitsprofil bei fortgeschr...
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L11 and VEGF-A, in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer Plan to initiate additional pivotal trials for pumitamig ...
Stellantis Reports 13% Year-Over-Year Increase in Q3 2025 Shipments and Net Revenues Stellantis Reports 13% Year-Over-Year Increase in Q3 2025 Shipments and Net Revenues Important Strategic Actions Taken and Early Signs of Commercial Progress;Significant Investments for Future Growth Already Announced Net revenues of €37.2 billion, up 13% compared to Q3 2024, primarily driven by growth in North America, Enlarged Europe and Middle East & Africa, while South America saw a moderate decrease.Consolidated shipments(1) totaled 1.3 million units, marking a 13% year-over-year increase (up 152,0...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.